These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23737958)

  • 1. An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis.
    Jiang FN; He HC; Zhang YQ; Yang DL; Huang JH; Zhu YX; Mo RJ; Chen G; Yang SB; Chen YR; Zhong WD; Zhou WL
    PLoS One; 2013; 8(5):e63941. PubMed ID: 23737958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systems biology-based classifier for hepatocellular carcinoma diagnosis.
    Zhang Y; Wang S; Li D; Zhnag J; Gu D; Zhu Y; He F
    PLoS One; 2011; 6(7):e22426. PubMed ID: 21829460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis.
    Han ZD; Zhang YQ; He HC; Dai QS; Qin GQ; Chen JH; Cai C; Fu X; Bi XC; Zhu JG; Liao DJ; Lu XP; Mo ZY; Zhu YP; Zhong WD
    Med Oncol; 2012 Dec; 29(4):2877-88. PubMed ID: 22215415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
    Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
    J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics in diagnosis of prostate cancer.
    Davalieva K; Polenakovic M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.
    Ummanni R; Mundt F; Pospisil H; Venz S; Scharf C; Barett C; Fälth M; Köllermann J; Walther R; Schlomm T; Sauter G; Bokemeyer C; Sültmann H; Schuppert A; Brümmendorf TH; Balabanov S
    PLoS One; 2011 Feb; 6(2):e16833. PubMed ID: 21347291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.
    Segalés L; Juanpere N; Gallarín N; Lorenzo M; López D; Perera-Bel J; Rodriguez-Vida A; Fumadó L; Cecchini L; Bellmunt J; Lloreta-Trull J; Hernández-Llodrà S
    Virchows Arch; 2024 Aug; 485(2):281-290. PubMed ID: 38017230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer.
    Huang Y; Jiang G; Liang X; Lan Z; Su Z; Wu H; Weng J; Jiang X
    Mol Med Rep; 2018 Oct; 18(4):3914-3922. PubMed ID: 30132530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
    Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
    PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Machine Learning Method for Predicting Biomarkers Associated with Prostate Cancer.
    Tong Y; Tan Z; Wang P; Gao X
    Front Biosci (Landmark Ed); 2023 Dec; 28(12):333. PubMed ID: 38179769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis.
    Barata PC; Magi-Galluzzi C; Gupta R; Dreicer R; Klein EA; Garcia JA
    Clin Genitourin Cancer; 2019 Oct; 17(5):366-372. PubMed ID: 31262501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
    Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
    J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis.
    Sun J; Li S; Wang F; Fan C; Wang J
    BMC Med Genet; 2019 Dec; 20(1):191. PubMed ID: 31791268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer.
    Davalieva K; Kostovska IM; Kiprijanovska S; Markoska K; Kubelka-Sabit K; Filipovski V; Stavridis S; Stankov O; Komina S; Petrusevska G; Polenakovic M
    Prostate; 2015 Oct; 75(14):1586-600. PubMed ID: 26074449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
    Schubert M; Spahn M; Kneitz S; Scholz CJ; Joniau S; Stroebel P; Riedmiller H; Kneitz B
    PLoS One; 2013; 8(6):e65064. PubMed ID: 23798998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer.
    Hou Q; Bing ZT; Hu C; Li MY; Yang KH; Mo Z; Xie XW; Liao JL; Lu Y; Horie S; Lou MW
    EBioMedicine; 2018 Jun; 32():234-244. PubMed ID: 29861410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implication and functional annotations of Rad50 expression in patients with prostate cancer.
    Xu WH; Wang J; Sheng HY; Qu YY; Wang HK; Zhu Y; Shi GH; Zhang HL; Ye DW
    J Cell Biochem; 2020 Jun; 121(5-6):3124-3134. PubMed ID: 31886567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.